DIQTA 1.0: Drug-Induced QT Prolongation Atlas

ISRADIPINE

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Ambiguous

Severity Score:1.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

CLINICAL PHARMACOLOGY
Electrophysiologic Effects
In general, no detrimental effects on the cardiac conduction system were seen with the use of isradipine. Electrophysiologic studies were conducted on patients with normal sinus and atrioventricular node function. Intravenous isradipine in doses which reduce systolic blood pressure did not affect PR, QRS, AH* or HV* intervals.
No changes were seen in Wenckebach cycle length, atrial, and ventricular refractory periods. Slight prolongation of QTc interval of 3% was seen in one study. Effects on sinus node recovery time (CSNRT) were mild or not seen.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24092

Other ADRs

287

38381300

Odds Ratio = 0.0

Drug Property Information

ATC Code(s):

C08CA03 - isradipine

C08CA0 -
C08CA - Dihydropyridine derivatives
C08C - SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08 - CALCIUM CHANNEL BLOCKERS
C - CARDIOVASCULAR SYSTEM

Active Ingredient:ISRADIPINE

Active Ingredient UNII:YO1UK1S598

Drugbank ID:DB00270

PubChem Compound:3784

CTD ID:D017275

PharmGKB:PA450131

CAS Number:75695-93-1

Dosage Form(s):capsule

Route(s) Of Administrator:oral

Daily Dose:

5.0 mg/day C08CA03

Chemical Structure:

SMILE Code:
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C

Reference

1: Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation.

[van Noord Charlotte,Aarnoudse Albert-Jan L H J,Eijgelsheim Mark,Sturkenboom Miriam C J M,Straus Sabine M J M,Hofman Albert,Kors Jan A,Newton-Cheh Christopher,Witteman Jacqueline C M,Stricker Bruno H Ch]
Pharmacogenet Genomics,2009 Apr;19(4):260-6. PMID: 19247217

Search for drugs: